Back

Plasminogen Activator Inhibitor-1 is internalized by endothelial cells via macropinocytosis to evade degradation

McAdow, M. E.; Ahmetaj, G.; Hauschel, R.; Eichmann, A.; Sessa, B. E.

2024-09-26 cell biology
10.1101/2024.09.26.615054 bioRxiv
Show abstract

Plasminogen activator inhibitor1 (PAI1) promotes hemostasis and is a biomarker of cardiovascular disease but accumulating evidence supports a role for PAI1 in intracellular biology. Recently, we found that PAI1 directly inhibits endothelial nitric oxide synthase (eNOS) and that exogenous PAI1 is internalized and traffics to eNOS. However, prior work has demonstrated that when PAI1 is internalized via LRP1 and uPAR on the cell surface and is internalized and degraded. Our objective was to identify the mechanism by which PAI1 is internalized and evades degradation. Here, we show that PAI1 is internalized by endothelial cells in an energy-dependent manner and persists in the cell for at least 6 hours. Entry is independent of LRP1, uPAR, or clathrin-mediated endocytosis. It is internalized in large vesicles, is inhibited by amiloride and nocodazole, and is partially dependent on CDC42, consistent with macropinocytosis. We propose that following internalization by macropinocytosis, PAI1 evades degradation, permitting eNOS inhibition.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.